BiotechTube

Losmapimod

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Facioscapulohumeral Muscular Dystrophy 1

Conditions

Facioscapulohumeral Muscular Dystrophy 1

Trial Timeline

Aug 23, 2019 → Oct 31, 2024

NCT ID
NCT04004000

About Losmapimod

Losmapimod is a phase 2 stage product being developed by Fulcrum Therapeutics for Facioscapulohumeral Muscular Dystrophy 1. The current trial status is terminated. This product is registered under clinical trial identifier NCT04004000. Target conditions include Facioscapulohumeral Muscular Dystrophy 1.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04264442Phase 2Terminated
NCT04004000Phase 2Terminated

Competing Products

12 competing products in Facioscapulohumeral Muscular Dystrophy 1

See all competitors
ProductCompanyStageHype Score
ACE-083 + ACE-083 or placeboMerckPhase 2
52
ACE-083MerckPhase 2
52
Placebo + RO7204239RochePhase 2
52
AOC-1020 + PlaceboAvidity BiosciencesPhase 3
74
Apitegromab + PlaceboScholar Rock HoldingPhase 2
49
Losmapimod oral tablet + Placebo oral tabletFulcrum TherapeuticsPhase 2
44
Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3
69
LosmapimodFulcrum TherapeuticsPhase 2
44
ATYR1940aTyr PharmaPhase 1/2
33
ATYR1940aTyr PharmaPhase 1/2
33
Placebo + ATYR1940aTyr PharmaPhase 1/2
33
ATYR1940aTyr PharmaPhase 1/2
33

Other Products from Fulcrum Therapeutics

Losmapimod oral tablet + Placebo oral tabletPhase 3
69
Losmapimod + Placebo oral tabletPhase 3
69
PociredirPhase 2
44
Losmapimod oral tablet + Placebo oral tabletPhase 2
44
LosmapimodPhase 2
44